



13 July 2010

The Company Announcements Platform
ASX Ltd
Sydney NSW 2000

BOARD CHANGE

Following the appointment of Mr Nick Woolf as a non executive director of the company on 22/4/2010, Mr A.P. Barton retired today as a non executive director.

Mr. Woolf is an accomplished biotechnology professional with 18 years experience in industry, equity research and investment banking.

He has acted as Head of European Biotechnology Research at ABN Amro and held similar roles at Robertson Stephens, Nomura and SBC Warburg.

Mr. Woolf is a qualified accountant and has an MA in Chemistry from the University of Oxford.

Mr. Woolf is already providing great benefit to Phylogica's international investor relations initiatives, and will continue to do so after his relocation to Australia in coming months

The Board of Phylogica thanks Mr. Barton very much for his past contribution at Board level and his continued support as one of our largest shareholders.

For further information, please contact:

Dr Paul Watt
CEO
Tel: +61 8 9382 8888
Mobile: +61 (0) 417 986 005
paulw@phylogica.com



About Phylogica (www.phylogica.com)

Phylogica is a biopharmaceutical company focusing on the discovery of Phylomer[®] peptides for its partners from the Pharmaceutical industry. Phylogica's discovery platform uses its proprietary Phylomer[®] libraries, a highly diverse collection of billions of Phylomer[®] peptides from across thousands of structural families, to provide a rich source of potent drug leads for a broad range of disease targets. Phylogica has gained significant leverage in the area of peptide drug discovery by establishing proprietary global rights for their Phylomer[®] libraries which constitute the most structurally diverse biologics libraries available. These libraries when combined with Phylogica's proprietary screening methods and significant know-how in the field of peptide drug discovery, constitute a powerful drug discovery platform, which offers the highest hit-rates for bioactive peptides as well as the highest quality of primary hits. Phylomer[®] libraries can access targets both outside and inside cells. In December 2009, Phylogica entered into an alliance with Roche to discover new sequences for intracellular targeting of biologicals